• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy
  • Reports
    • Diabetes Technology Innovations Special Report
    • Continuous Glucose Monitoring (CGM) Market Report

Eyenovia sets range for IPO

January 10, 2018 By Sarah Faulkner

EyenoviaN.Y.-based startup Eyenovia updated its regulatory filings to reveal that it plans to offer 2.73 million shares priced between $10 – $12 apiece in its initial public offering.

The 7-person company, which is developing a device to deliver small doses of drugs to the eye, is applying to list on the Nasdaq exchange under the symbol, “EYEN”.

Eyenovia first announced its IPO in December last year, writing that it planned to use the funds to support clinical trials of its drug-delivery tech.

The company uses a piezo-electric dispensation technology to deliver microdoses of drugs topically to the eye. The device tracks patient compliance and is designed to help avoid the adverse events linked to treating eye diseases, which Eyenovia hypothesizes are due to the large volume of drug delivered by traditional eye droppers.

Eyenovia plans to use the $7.4 million it has on-hand plus the cash from its IPO to finish Phase III trials for MicroProst, its chronic angle closure glaucoma product, and for MicroStat, a product used to dilate the eyes during an eye exam.

The company noted that it is pursuing a 505(b)(2) pathway since only the drug comes into contact with the body.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Funding Roundup, Optical/Ophthalmic, Pharmaceuticals, Wall Street Beat Tagged With: Eyenovia Inc.

IN CASE YOU MISSED IT

  • Tandem Diabetes Care names successor as CEO Sheridan retires
  • MiniMed names new CMO ahead of planned retirement
  • Insulet earnings trounce Q3 estimates as it narrows guidance
  • Dexcom Q3 earnings top forecasts, as it looks ahead to type 2 coverage
  • Sensonics launches human feasibility study for transmitter-free Eversense CGM

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.
MDO

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
About
Contact us
Listen to our Weekly Podcasts
Advertise

Copyright © 2026 · Arrowfly LLC. All Rights Reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly.

Privacy Policy | Terms & Conditions | RSS